Novo Nordisk UK stockpiling medicines in case of 'no deal'

4 September 2018

As the biggest supplier of insulin in the UK, the consequences of Danish diabetes company Novo Nordisk (NOV: N) failing to get its products through customs could be disastrous if there are hold-ups due to a ‘no deal’ Brexit.

Thankfully, the company is increasing stock of insulin products to approximately 16 weeks from the fourth quarter of 2018 as part of its preparations for the ‘no deal’ scenario of the UK and European Union (EU) going their separate ways without an agreement.

Pinder Sahota, corporate vice president of Novo Nordisk UK, said: “Our first commitment is to ensure that patients treated with our medicines remain unaffected in the event of a ‘no-deal’ Brexit. We are working closely with trade associations in the UK and the EU to ensure that the interests of our patients are at the forefront of negotiations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK